Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease
AOSD Podcast
4 episodes
4 days ago
Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease.
All content for Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease is the property of AOSD Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease.
Goals of treatment: control inflammation, prevent joint and organ damage, minimize treatment-related adverse events; relieve patient burden
A wide variety of non-biologic and biologic medications are used for treatment, but are supported with limited evidence
Canakinumab is the only medication approved by the US Food and Drug Administration for the treatment of patients with adult-onset Still’s disease based, in part, on the results of the phase 3 CONSIDER trial
There is no standardized approach to patient monitoring, but is closely tied to the goals of treatment
Exploring Best Practices for Diagnosis & Management of Adult-Onset Still's Disease
Adult-onset Still’s disease (AOSD) is a rare, polygenic autoinflammatory syndrome with a pathogenesis similar to systemic juvenile inflammatory arthritis. Join Drs. Petros Efthimiou and Olga Petryna as they discuss making the diagnosis of AOSD through interpretation of clinical and laboratory findings and careful exclusion of other diseases. The faculty review the evidence related to the variety of medications often used to treat patients with AOSD, focusing on canakinumab, the only medication approved in the United States for the disease.
